Business Unit Leaders

Dr. Colin Collins, PhD

Dr. Colin Collins, PhD

Director, Laboratory for Advanced Genome Analysis
Professor, Department of Urologic Sciences, UBC
Senior Research Scientist, Vancouver Prostate Centre

Dr. Collins is a professor of Urologic Sciences in the school of Medicine at the University of British Columbia. In addition, Dr. Collins is an associate adjunct professor at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center and has visiting Professorships at Fudan University and BGI in China. Dr. Collins’ current research is best described as translational genomics where mathematics, computer science, genomics and clinical science converge in systems biology, diagnostics, and ultimately therapeutics.

Dr. David Huntsman MD, FRCPC, FCCMG

Dr. David Huntsman MD, FRCPC, FCCMG

Director, Centre for Translational and Applied Genomics (CTAG)
Co-Director,Genetic Pathology Evaluation Centre (GPEC)
Director and a co-founder, OvCaRe

Associate Professor, Pathology and Laboratory Medicine, UBC

Dr. Huntsman has active research programs, which are focused on hereditary gastric cancer and the development of predictive and prognostic tissue-based cancer biomarkers for a wide variety of tumour types. His gastric cancer research has resulted in the discovery of over half of known CDH1mutations. Dr. Huntsman was also a member of the research team that discovered EMSY, a BRCA2interacting protein. The amplification of the EMSY gene is clinically significant in breast and possibly ovarian cancers and over expression of a truncated form of EMSY results in dramatic chromosomal instability.

Dr. Mads Daugaard, PhD

Dr. Mads Daugaard, PhD

Assistant Professor, Department of Urologic Sciences, UBC
Senior Research Scientist, Vancouver Prostate Centre

Dr. Daugaard heads the Molecular Pathology and Cell Imaging Core at the Prostate Centre. His research focuses on molecular and biochemical events underlying alternative polyadenylation of mRNAs, chromatin context-dependent DNA repair, and development of resistance to chemotherapy. Dr. Daugaard is a founder and Chief Scientific Officer of VAR2 Pharmaceuticals ApS, a Danish biotechnology company focused on the development of a directed delivery system for cancer therapeutics.

Dr. Artem Cherkasov, PhD

Dr. Artem Cherkasov, PhD

Professor, Department of Urologic Sciences, UBC
Senior Research Scientist, Vancouver Prostate Centre

Dr. Cherkasov is an Associate Professor in the Faculty of Medicine at the University of British Columbia. His research interests include computer-aided drug design, applications of artificial intelligence in structure-activity modelling for bioactive substances, development large-scale bioinformatics and genomics tools and molecular modelling techniques.

Dr. Emma S. Tomlinson Guns, PhD

Dr. Emma S. Tomlinson Guns, PhD

Associate Professor, Department of Urologic Sciences, UBC
Senior Research Scientist, Vancouver Prostate Centre

Dr. Tomlinson Guns heads the Analytical Pharmacology Core (APC) and Natural Products Research Program at the Prostate Centre. Her primary research focus is orientated around the use of natural health products and dietary supplements in prostate cancer and her lab is currently working with several compounds / extracts of interest in prostate tumor models to examine their pharmacokinetics and tissue distribution, toxicity, metabolism and molecular mechanism of the action. They are investigating product quality, as well as the concurrent use of natural products with conventional chemotherapeutics / treatment strategies to discern both beneficial and adverse interactions.

Dr. Christopher Ong, PhD

Dr. Christopher Ong, PhD

Assistant Professor, Department of Urologic Sciences, UBC
Senior Research Scientist, Vancouver Prostate Centre

The primary focus of Dr. Ong’s research program is to understand the molecular mechanisms that govern the progression of prostate cancer from a state of androgen sensitivity to hormone independence, in particular on the PTEN tumour suppressor gene, which is among the most frequently mutated genes in cancer. Dr. Ong’s laboratory is also involved in the development of unique prostate tumour model systems. He was also involved in the discovery and development of a novel class of small molecule agonists of SHIP. Dr. Ong Is a scientific founder of Aquinox Pharmaceuticals Inc., a biopharmaceutical company focused on development of targeted small molecule therapeutics for treatment of cancer and inflammation.

Dr. Kim Chi, MD, FRCPC

Dr. Kim Chi, MD, FRCPC

Associate Director, Clinical Research, Vancouver Prostate Centre
Senior Research Scientist, Vancouver Prostate Centre
Regional Medical Director, BC Cancer Agency – Vancouver Centre
Medical Oncologist, BC Cancer Agency – Vancouver Centre
Director, Clinical Research, BC Cancer Agency
Professor, Department of Medicine, UBC

Dr. Chi is a medical oncologist with the BC Cancer Agency and the Vancouver Prostate Centre, Director of Clinical Research at the BC Cancer Agency, and Regional Medical Director at the BC Cancer Agency – Vancouver Centre. Dr. Chi’s research is focused in the area of genitourinary cancers with a special interest in prostate cancer and investigational new drugs. This includes phase I, II, and III clinical trials, therapeutic use of antisense oligonucleotides, and mechanisms of treatment resistance. He has led numerous national and international clinical trials of novel therapies for patients with prostate cancer.

News